Emergent Biosolutions (EBS) AI Stock Analysis

• Market Cap: $586.65M
• Dividend Yield: N/A
• Average Volume (3M): 1.28M
• Price to Earnings (P/E): 8.6
• Beta (1Y): 3.09
• Revenue Growth: -29.91%
• EPS Growth: N/A
• Country: US
• Employees: 900
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.06
• Shares Outstanding: 52,519,962
• 10 Day Avg. Volume: 926,528
• 30 Day Avg. Volume: 1,276,416
• PEG Ratio: 0.04
• Price to Book (P/B): 1.05
• Price to Sales (P/S): 0.49
• P/FCF Ratio: 14.15
• Enterprise Value/Market Cap: 1.57
• Enterprise Value/Revenue: 1.17
• Enterprise Value/Gross Profit: 2.02
• Enterprise Value/Ebitda: 4.26
• 1Y Price Target: $15.00
• Price Target Upside: 34.29% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): 1.27
• Revenue Forecast (FY): $799.07M

• Rating: 69 Neutral
• Price Target: $12.00 ▲(7.43% Upside)

The stock's strong technical momentum and positive earnings call are significant strengths, indicating potential for growth. However, financial performance concerns, particularly in cash flow and leverage, moderate the overall score.

Positive Factors

Improved Profitability

The positive net profit margin indicates a recovery in profitability, suggesting effective cost management and potential for sustained earnings growth.

Strong Liquidity Position

A robust liquidity position provides financial flexibility for strategic investments and debt reduction, supporting long-term business stability.

Naloxone Business Growth

Continued growth in the naloxone business strengthens market leadership and enhances revenue diversification, supporting long-term growth prospects.

Negative Factors

High Leverage

High leverage can pose risks to financial stability, potentially limiting the company's ability to invest in growth opportunities or weather economic downturns.

Revenue Decline

A decline in revenue highlights challenges in maintaining growth momentum, which could impact long-term financial performance and market competitiveness.

Weak Cash Flow Generation

Weak cash flow generation limits the company's ability to fund operations and investments, potentially constraining future growth and strategic initiatives.

Emergent Biosolutions Business Overview & Revenue Model

Company Description

Emergent BioSolutions (EBS) is a global life sciences company focused on providing solutions for public health threats. Operating primarily in the biopharmaceutical sector, EBS specializes in developing and manufacturing vaccines, therapeutics, and other products for infectious diseases, including biodefense. The company is known for its core products, such as vaccines for anthrax and smallpox, as well as its work in emerging infectious diseases and specialty pharmaceuticals.

How the Company Makes Money

Emergent BioSolutions generates revenue through multiple streams, primarily by selling its vaccines and therapeutics to government agencies, including the U.S. Department of Health and Human Services and the Department of Defense, as well as international governments. The company's revenue model includes contract manufacturing services for third-party clients, which provides additional income through production capabilities. Significant partnerships, particularly with governmental organizations and large pharmaceutical companies, enhance its earnings by securing multi-year contracts and funding for research and development. Moreover, the company also benefits from grants and funding related to biodefense initiatives and public health preparedness programs.

Emergent Biosolutions Financial Statement Overview

Summary

Emergent Biosolutions shows signs of recovery in profitability with improved margins, but faces challenges in revenue growth and cash flow generation. High leverage remains a concern, although improved return on equity is positive. Focus on enhancing cash flow and reducing debt is crucial.

Income Statement

Emergent Biosolutions has shown a decline in revenue over the TTM period, with a negative revenue growth rate of -7.36%. However, the company has improved its gross profit margin to 57.8% in the TTM, indicating strong cost management. The net profit margin has also turned positive at 9.62%, a significant improvement from previous losses, suggesting a recovery in profitability. Despite these improvements, the EBIT and EBITDA margins remain moderate at 15.13% and 27.37%, respectively.

Balance Sheet

The company's debt-to-equity ratio is relatively high at 1.14, indicating significant leverage, which could pose risks if earnings do not continue to improve. However, the return on equity has improved to 14.09% in the TTM, reflecting better utilization of equity to generate profits. The equity ratio stands at 39.86%, suggesting a balanced capital structure but with room for improvement in reducing debt levels.

Cash Flow

Emergent Biosolutions has faced challenges in cash flow generation, with a drastic decline in free cash flow growth at -99.10% in the TTM. The operating cash flow to net income ratio is low at 0.095, indicating weak cash conversion from earnings. Additionally, the free cash flow to net income ratio is 0.108, suggesting limited free cash flow relative to net income, which could constrain future investments or debt repayments.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	788.90M	1.04B	1.05B	1.12B	1.77B	1.58B
Gross Profit	456.00M	375.40M	360.00M	473.00M	793.20M	863.10M
EBITDA	215.90M	53.40M	-47.00M	15.70M	504.20M	609.20M
Net Income	75.90M	-190.60M	-760.50M	-211.60M	219.50M	305.80M
Balance Sheet
Total Assets	1.46B	1.39B	1.82B	3.17B	2.96B	2.88B
Cash, Cash Equivalents and Short-Term Investments	245.50M	99.50M	111.70M	642.60M	576.30M	621.30M
Total Debt	663.10M	676.10M	860.20M	1.43B	871.00M	923.00M
Total Liabilities	878.50M	906.90M	1.17B	1.78B	1.35B	1.44B
Stockholders Equity	582.50M	482.80M	649.30M	1.39B	1.61B	1.45B
Cash Flow
Free Cash Flow	1.40M	35.80M	-257.90M	-149.90M	96.10M	395.00M
Operating Cash Flow	13.00M	58.70M	-206.30M	-34.10M	321.10M	536.90M
Investing Cash Flow	101.90M	125.20M	212.30M	-381.30M	-225.00M	-151.90M
Financing Cash Flow	-22.20M	-190.00M	-535.70M	481.20M	-141.00M	69.50M

Emergent Biosolutions Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 11.17
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For EBS, the sentiment is Positive. The current price of 11.17 is above the 20-day moving average (MA) of 10.51, above the 50-day MA of 9.80, and above the 200-day MA of 7.40, indicating a bullish trend. The MACD of 0.25 indicates Negative momentum. The RSI at 58.92 is Neutral, neither overbought nor oversold. The STOCH value of 93.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for EBS.

Emergent Biosolutions Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AMPH	76 Outperform	$1.26B	12.13	14.84%	―	-0.03%	-27.66%
SIGA	73 Outperform	$582.87M	7.09	39.94%	―	-0.85%	-13.50%
DVAX	70 Outperform	$1.34B	―	-7.14%	―	26.73%	-310.39%
PCRX	69 Neutral	$981.78M	―	2.90%	―	3.14%	―
EBS	69 Neutral	$586.65M	8.63	13.92%	―	-29.91%	―
ANIP	64 Neutral	$1.90B	51.74	7.83%	―	48.87%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Emergent Biosolutions Corporate Events

Emergent BioSolutions Announces Board Member Retirement

Emergent BioSolutions announced the retirement of Dr. Louis W. Sullivan from its Board of Directors, effective November 14, 2025, after 19 years of service. Dr. Sullivan, who has been a key advisor and leader, contributed significantly to the company’s mission and strategic decisions, including its ongoing multi-year transformation.

The most recent analyst rating on (EBS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions’ Earnings Call Highlights Strong Growth

Emergent BioSolutions’ recent earnings call painted a picture of optimism and robust financial health. The company reported a strong quarter, surpassing revenue and profitability expectations, and subsequently increased its financial guidance for the year. Despite some challenges, such as a decline in year-to-date revenues due to past divestitures and variability in Canadian sales, the overall sentiment remained positive, buoyed by significant growth in the naloxone business and international revenue.

Emergent BioSolutions Reports Strong Q3 2025 Results

Emergent BioSolutions Inc. is a biopharmaceutical company focused on providing medical countermeasures for biological threats and public health emergencies, operating primarily in the healthcare sector with a unique emphasis on products like vaccines and treatments for diseases such as anthrax and smallpox.

Emergent BioSolutions Raises Full-Year Revenue Guidance

On October 29, 2025, Emergent BioSolutions reported its financial results for the third quarter of 2025, with total revenues of $231.1 million, surpassing its guidance by $21 million. Despite a decrease in revenues compared to the previous year, the company experienced strong growth in its naloxone franchise, driven by NARCAN® Nasal Spray, and secured multiple contract modifications for its medical countermeasures products. The company raised its full-year revenue and profitability guidance, reflecting confidence in its product demand and strategic positioning in the market.

The most recent analyst rating on (EBS) stock is a Buy with a $10.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions Secures $56 Million Contract Modification

On September 5, 2025, Emergent BioSolutions received a $56 million contract modification from the U.S. Department of Health and Human Services to supply ACAM2000, a smallpox and mpox vaccine, under an existing 10-year contract. This modification underscores the ongoing collaboration between Emergent and the U.S. government to prioritize public health preparedness, with deliveries expected to begin in September 2025, contributing to projected sales of over $120 million for the year.

The most recent analyst rating on (EBS) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions Advances Pediatric Botulism Antitoxin Study

Study Overview: Emergent BioSolutions is conducting a study titled ‘Pharmacokinetics of Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) – (Equine) (BAT®) in Pediatric Patients With a Confirmed or Suspected Exposure to Botulinum Neurotoxin.’ The study aims to verify pediatric dosing recommendations for the BAT product in children exposed to botulinum neurotoxin, ensuring safety and efficacy.

Emergent BioSolutions Secures $30M BARDA Contract Extension

On August 29, 2025, Emergent BioSolutions received a $30 million contract modification from the Biomedical Advanced Research and Development Authority (BARDA) to supply additional doses of CYFENDUS™, an anthrax vaccine. This contract, part of an ongoing agreement since 2016, underscores Emergent’s commitment to supporting U.S. national security priorities by ensuring the availability of medical countermeasures against anthrax threats. The deliveries are expected to start within the current calendar year and conclude by March 2026, highlighting Emergent’s strategic role in biodefense.

The most recent analyst rating on (EBS) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.

Emergent BioSolutions’ AIGIV Study: A Potential Game-Changer for Inhalational Anthrax Treatment

Emergent BioSolutions is spearheading a critical study titled ‘A Field Study for the Evaluation of AIGIV Clinical Benefit and Safety in the Treatment of Patients With Inhalational Anthrax in a Broad Exposure Event Scenario.’ The study aims to assess the safety and clinical benefits of AIGIV (ANTHRASIL®) for treating inhalational anthrax, a severe and potentially fatal condition. This research is significant as it will provide vital insights into the effectiveness of AIGIV during a major anthrax exposure event, focusing on patient survival and illness extent.

Emergent BioSolutions’ AIGIV Study: A Potential Game-Changer for Anthrax Treatment

Study Overview: Emergent BioSolutions is conducting an observational study titled ‘An Observational Clinical Study of AIGIV Use in Sporadic Cases of Systemic Anthrax.’ The study aims to assess the safety and clinical benefits of AIGIV (ANTHRASIL®) in treating patients with systemic anthrax. This research is significant as it seeks to gather data on the extent of anthrax illness, survival rates, and serum concentrations of AIGIV and anthrax toxins in affected patients.